nodes	percent_of_prediction	percent_of_DWPC	metapath
Hydromorphone—PTGS1—Ifosfamide—testicular cancer	0.207	0.34	CbGbCtD
Hydromorphone—PTGS1—Etoposide—testicular cancer	0.0988	0.163	CbGbCtD
Hydromorphone—CYP2C9—Ifosfamide—testicular cancer	0.0832	0.137	CbGbCtD
Hydromorphone—CYP3A4—Ifosfamide—testicular cancer	0.0484	0.0797	CbGbCtD
Hydromorphone—CYP2C9—Cisplatin—testicular cancer	0.0405	0.0666	CbGbCtD
Hydromorphone—CYP2D6—Vinblastine—testicular cancer	0.0404	0.0665	CbGbCtD
Hydromorphone—CYP3A4—Vinblastine—testicular cancer	0.0257	0.0423	CbGbCtD
Hydromorphone—CYP2D6—Doxorubicin—testicular cancer	0.0248	0.0408	CbGbCtD
Hydromorphone—CYP3A4—Etoposide—testicular cancer	0.0231	0.0381	CbGbCtD
Hydromorphone—CYP3A4—Doxorubicin—testicular cancer	0.0158	0.026	CbGbCtD
Hydromorphone—Infestation—Doxorubicin—testicular cancer	0.000265	0.000675	CcSEcCtD
Hydromorphone—Infestation NOS—Doxorubicin—testicular cancer	0.000265	0.000675	CcSEcCtD
Hydromorphone—Drowsiness—Doxorubicin—testicular cancer	0.000265	0.000675	CcSEcCtD
Hydromorphone—Visual impairment—Methotrexate—testicular cancer	0.000265	0.000675	CcSEcCtD
Hydromorphone—Vomiting—Ifosfamide—testicular cancer	0.000262	0.000668	CcSEcCtD
Hydromorphone—Hypersensitivity—Cisplatin—testicular cancer	0.000262	0.000668	CcSEcCtD
Hydromorphone—Bradycardia—Epirubicin—testicular cancer	0.000262	0.000667	CcSEcCtD
Hydromorphone—Rash—Ifosfamide—testicular cancer	0.00026	0.000663	CcSEcCtD
Hydromorphone—Dermatitis—Ifosfamide—testicular cancer	0.00026	0.000662	CcSEcCtD
Hydromorphone—Urticaria—Etoposide—testicular cancer	0.000259	0.00066	CcSEcCtD
Hydromorphone—Stomatitis—Doxorubicin—testicular cancer	0.000258	0.000658	CcSEcCtD
Hydromorphone—Rhinitis—Epirubicin—testicular cancer	0.000258	0.000657	CcSEcCtD
Hydromorphone—Abdominal pain—Etoposide—testicular cancer	0.000258	0.000656	CcSEcCtD
Hydromorphone—Body temperature increased—Etoposide—testicular cancer	0.000258	0.000656	CcSEcCtD
Hydromorphone—Eye disorder—Methotrexate—testicular cancer	0.000257	0.000654	CcSEcCtD
Hydromorphone—Tinnitus—Methotrexate—testicular cancer	0.000256	0.000653	CcSEcCtD
Hydromorphone—Hypoaesthesia—Epirubicin—testicular cancer	0.000256	0.000652	CcSEcCtD
Hydromorphone—Asthenia—Cisplatin—testicular cancer	0.000255	0.00065	CcSEcCtD
Hydromorphone—Cardiac disorder—Methotrexate—testicular cancer	0.000255	0.00065	CcSEcCtD
Hydromorphone—Sweating—Doxorubicin—testicular cancer	0.000254	0.000647	CcSEcCtD
Hydromorphone—Urinary tract disorder—Epirubicin—testicular cancer	0.000254	0.000647	CcSEcCtD
Hydromorphone—Oedema peripheral—Epirubicin—testicular cancer	0.000253	0.000645	CcSEcCtD
Hydromorphone—Connective tissue disorder—Epirubicin—testicular cancer	0.000253	0.000644	CcSEcCtD
Hydromorphone—Urethral disorder—Epirubicin—testicular cancer	0.000252	0.000642	CcSEcCtD
Hydromorphone—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000251	0.000639	CcSEcCtD
Hydromorphone—Angiopathy—Methotrexate—testicular cancer	0.000249	0.000635	CcSEcCtD
Hydromorphone—Immune system disorder—Methotrexate—testicular cancer	0.000248	0.000632	CcSEcCtD
Hydromorphone—Visual impairment—Epirubicin—testicular cancer	0.000248	0.000631	CcSEcCtD
Hydromorphone—Mediastinal disorder—Methotrexate—testicular cancer	0.000248	0.000631	CcSEcCtD
Hydromorphone—Chills—Methotrexate—testicular cancer	0.000247	0.000628	CcSEcCtD
Hydromorphone—Nausea—Ifosfamide—testicular cancer	0.000245	0.000624	CcSEcCtD
Hydromorphone—Diarrhoea—Cisplatin—testicular cancer	0.000243	0.00062	CcSEcCtD
Hydromorphone—Bradycardia—Doxorubicin—testicular cancer	0.000242	0.000617	CcSEcCtD
Hydromorphone—Mental disorder—Methotrexate—testicular cancer	0.000241	0.000613	CcSEcCtD
Hydromorphone—Eye disorder—Epirubicin—testicular cancer	0.00024	0.000612	CcSEcCtD
Hydromorphone—Hypersensitivity—Etoposide—testicular cancer	0.00024	0.000612	CcSEcCtD
Hydromorphone—Tinnitus—Epirubicin—testicular cancer	0.00024	0.000611	CcSEcCtD
Hydromorphone—Erythema—Methotrexate—testicular cancer	0.000239	0.000609	CcSEcCtD
Hydromorphone—Malnutrition—Methotrexate—testicular cancer	0.000239	0.000609	CcSEcCtD
Hydromorphone—Flushing—Epirubicin—testicular cancer	0.000239	0.000608	CcSEcCtD
Hydromorphone—Cardiac disorder—Epirubicin—testicular cancer	0.000239	0.000608	CcSEcCtD
Hydromorphone—Rhinitis—Doxorubicin—testicular cancer	0.000239	0.000608	CcSEcCtD
Hydromorphone—Hypoaesthesia—Doxorubicin—testicular cancer	0.000237	0.000603	CcSEcCtD
Hydromorphone—Urinary tract disorder—Doxorubicin—testicular cancer	0.000235	0.000599	CcSEcCtD
Hydromorphone—Oedema peripheral—Doxorubicin—testicular cancer	0.000234	0.000597	CcSEcCtD
Hydromorphone—Dysgeusia—Methotrexate—testicular cancer	0.000234	0.000597	CcSEcCtD
Hydromorphone—Asthenia—Etoposide—testicular cancer	0.000234	0.000596	CcSEcCtD
Hydromorphone—Connective tissue disorder—Doxorubicin—testicular cancer	0.000234	0.000596	CcSEcCtD
Hydromorphone—Angiopathy—Epirubicin—testicular cancer	0.000233	0.000594	CcSEcCtD
Hydromorphone—Urethral disorder—Doxorubicin—testicular cancer	0.000233	0.000594	CcSEcCtD
Hydromorphone—Immune system disorder—Epirubicin—testicular cancer	0.000232	0.000592	CcSEcCtD
Hydromorphone—Mediastinal disorder—Epirubicin—testicular cancer	0.000232	0.00059	CcSEcCtD
Hydromorphone—Back pain—Methotrexate—testicular cancer	0.000231	0.000589	CcSEcCtD
Hydromorphone—Chills—Epirubicin—testicular cancer	0.000231	0.000588	CcSEcCtD
Hydromorphone—Pruritus—Etoposide—testicular cancer	0.000231	0.000587	CcSEcCtD
Hydromorphone—Arrhythmia—Epirubicin—testicular cancer	0.00023	0.000585	CcSEcCtD
Hydromorphone—Visual impairment—Doxorubicin—testicular cancer	0.000229	0.000584	CcSEcCtD
Hydromorphone—Vomiting—Cisplatin—testicular cancer	0.000226	0.000576	CcSEcCtD
Hydromorphone—Vision blurred—Methotrexate—testicular cancer	0.000225	0.000574	CcSEcCtD
Hydromorphone—Mental disorder—Epirubicin—testicular cancer	0.000225	0.000574	CcSEcCtD
Hydromorphone—Rash—Cisplatin—testicular cancer	0.000224	0.000571	CcSEcCtD
Hydromorphone—Dermatitis—Cisplatin—testicular cancer	0.000224	0.000571	CcSEcCtD
Hydromorphone—Erythema—Epirubicin—testicular cancer	0.000224	0.00057	CcSEcCtD
Hydromorphone—Malnutrition—Epirubicin—testicular cancer	0.000224	0.00057	CcSEcCtD
Hydromorphone—Diarrhoea—Etoposide—testicular cancer	0.000223	0.000568	CcSEcCtD
Hydromorphone—Eye disorder—Doxorubicin—testicular cancer	0.000222	0.000566	CcSEcCtD
Hydromorphone—Ill-defined disorder—Methotrexate—testicular cancer	0.000222	0.000565	CcSEcCtD
Hydromorphone—Tinnitus—Doxorubicin—testicular cancer	0.000222	0.000565	CcSEcCtD
Hydromorphone—Cardiac disorder—Doxorubicin—testicular cancer	0.000221	0.000563	CcSEcCtD
Hydromorphone—Flushing—Doxorubicin—testicular cancer	0.000221	0.000563	CcSEcCtD
Hydromorphone—Flatulence—Epirubicin—testicular cancer	0.000221	0.000562	CcSEcCtD
Hydromorphone—Tension—Epirubicin—testicular cancer	0.00022	0.00056	CcSEcCtD
Hydromorphone—Dysgeusia—Epirubicin—testicular cancer	0.000219	0.000558	CcSEcCtD
Hydromorphone—Nervousness—Epirubicin—testicular cancer	0.000217	0.000554	CcSEcCtD
Hydromorphone—Back pain—Epirubicin—testicular cancer	0.000217	0.000552	CcSEcCtD
Hydromorphone—Angiopathy—Doxorubicin—testicular cancer	0.000216	0.00055	CcSEcCtD
Hydromorphone—Malaise—Methotrexate—testicular cancer	0.000216	0.00055	CcSEcCtD
Hydromorphone—Dizziness—Etoposide—testicular cancer	0.000216	0.000549	CcSEcCtD
Hydromorphone—Muscle spasms—Epirubicin—testicular cancer	0.000215	0.000548	CcSEcCtD
Hydromorphone—Immune system disorder—Doxorubicin—testicular cancer	0.000215	0.000547	CcSEcCtD
Hydromorphone—Vertigo—Methotrexate—testicular cancer	0.000215	0.000547	CcSEcCtD
Hydromorphone—Mediastinal disorder—Doxorubicin—testicular cancer	0.000214	0.000546	CcSEcCtD
Hydromorphone—Leukopenia—Methotrexate—testicular cancer	0.000214	0.000545	CcSEcCtD
Hydromorphone—Chills—Doxorubicin—testicular cancer	0.000214	0.000544	CcSEcCtD
Hydromorphone—Arrhythmia—Doxorubicin—testicular cancer	0.000213	0.000541	CcSEcCtD
Hydromorphone—Nausea—Cisplatin—testicular cancer	0.000211	0.000538	CcSEcCtD
Hydromorphone—Vision blurred—Epirubicin—testicular cancer	0.000211	0.000537	CcSEcCtD
Hydromorphone—Cough—Methotrexate—testicular cancer	0.000209	0.000532	CcSEcCtD
Hydromorphone—Mental disorder—Doxorubicin—testicular cancer	0.000208	0.000531	CcSEcCtD
Hydromorphone—Ill-defined disorder—Epirubicin—testicular cancer	0.000208	0.000529	CcSEcCtD
Hydromorphone—Convulsion—Methotrexate—testicular cancer	0.000207	0.000528	CcSEcCtD
Hydromorphone—Vomiting—Etoposide—testicular cancer	0.000207	0.000528	CcSEcCtD
Hydromorphone—Malnutrition—Doxorubicin—testicular cancer	0.000207	0.000528	CcSEcCtD
Hydromorphone—Erythema—Doxorubicin—testicular cancer	0.000207	0.000528	CcSEcCtD
Hydromorphone—Agitation—Epirubicin—testicular cancer	0.000206	0.000524	CcSEcCtD
Hydromorphone—Rash—Etoposide—testicular cancer	0.000206	0.000524	CcSEcCtD
Hydromorphone—Dermatitis—Etoposide—testicular cancer	0.000205	0.000523	CcSEcCtD
Hydromorphone—Headache—Etoposide—testicular cancer	0.000204	0.00052	CcSEcCtD
Hydromorphone—Flatulence—Doxorubicin—testicular cancer	0.000204	0.00052	CcSEcCtD
Hydromorphone—Myalgia—Methotrexate—testicular cancer	0.000204	0.000519	CcSEcCtD
Hydromorphone—Arthralgia—Methotrexate—testicular cancer	0.000204	0.000519	CcSEcCtD
Hydromorphone—Chest pain—Methotrexate—testicular cancer	0.000204	0.000519	CcSEcCtD
Hydromorphone—Tension—Doxorubicin—testicular cancer	0.000203	0.000518	CcSEcCtD
Hydromorphone—Dysgeusia—Doxorubicin—testicular cancer	0.000203	0.000517	CcSEcCtD
Hydromorphone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000202	0.000515	CcSEcCtD
Hydromorphone—Malaise—Epirubicin—testicular cancer	0.000202	0.000514	CcSEcCtD
Hydromorphone—Discomfort—Methotrexate—testicular cancer	0.000201	0.000513	CcSEcCtD
Hydromorphone—Nervousness—Doxorubicin—testicular cancer	0.000201	0.000512	CcSEcCtD
Hydromorphone—Vertigo—Epirubicin—testicular cancer	0.000201	0.000512	CcSEcCtD
Hydromorphone—Syncope—Epirubicin—testicular cancer	0.000201	0.000511	CcSEcCtD
Hydromorphone—Leukopenia—Epirubicin—testicular cancer	0.0002	0.00051	CcSEcCtD
Hydromorphone—Back pain—Doxorubicin—testicular cancer	0.0002	0.00051	CcSEcCtD
Hydromorphone—Muscle spasms—Doxorubicin—testicular cancer	0.000199	0.000507	CcSEcCtD
Hydromorphone—Palpitations—Epirubicin—testicular cancer	0.000198	0.000504	CcSEcCtD
Hydromorphone—Confusional state—Methotrexate—testicular cancer	0.000197	0.000501	CcSEcCtD
Hydromorphone—Loss of consciousness—Epirubicin—testicular cancer	0.000197	0.000501	CcSEcCtD
Hydromorphone—Cough—Epirubicin—testicular cancer	0.000195	0.000498	CcSEcCtD
Hydromorphone—Anaphylactic shock—Methotrexate—testicular cancer	0.000195	0.000497	CcSEcCtD
Hydromorphone—Vision blurred—Doxorubicin—testicular cancer	0.000195	0.000497	CcSEcCtD
Hydromorphone—Convulsion—Epirubicin—testicular cancer	0.000194	0.000494	CcSEcCtD
Hydromorphone—Infection—Methotrexate—testicular cancer	0.000194	0.000494	CcSEcCtD
Hydromorphone—Nausea—Etoposide—testicular cancer	0.000194	0.000493	CcSEcCtD
Hydromorphone—Hypertension—Epirubicin—testicular cancer	0.000193	0.000492	CcSEcCtD
Hydromorphone—Ill-defined disorder—Doxorubicin—testicular cancer	0.000192	0.00049	CcSEcCtD
Hydromorphone—Nervous system disorder—Methotrexate—testicular cancer	0.000191	0.000488	CcSEcCtD
Hydromorphone—Arthralgia—Epirubicin—testicular cancer	0.000191	0.000485	CcSEcCtD
Hydromorphone—Chest pain—Epirubicin—testicular cancer	0.000191	0.000485	CcSEcCtD
Hydromorphone—Myalgia—Epirubicin—testicular cancer	0.000191	0.000485	CcSEcCtD
Hydromorphone—Agitation—Doxorubicin—testicular cancer	0.00019	0.000485	CcSEcCtD
Hydromorphone—Anxiety—Epirubicin—testicular cancer	0.00019	0.000484	CcSEcCtD
Hydromorphone—Skin disorder—Methotrexate—testicular cancer	0.00019	0.000483	CcSEcCtD
Hydromorphone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000189	0.000482	CcSEcCtD
Hydromorphone—Hyperhidrosis—Methotrexate—testicular cancer	0.000189	0.000481	CcSEcCtD
Hydromorphone—Discomfort—Epirubicin—testicular cancer	0.000188	0.00048	CcSEcCtD
Hydromorphone—Malaise—Doxorubicin—testicular cancer	0.000187	0.000476	CcSEcCtD
Hydromorphone—Dry mouth—Epirubicin—testicular cancer	0.000186	0.000475	CcSEcCtD
Hydromorphone—Vertigo—Doxorubicin—testicular cancer	0.000186	0.000474	CcSEcCtD
Hydromorphone—Anorexia—Methotrexate—testicular cancer	0.000186	0.000474	CcSEcCtD
Hydromorphone—Syncope—Doxorubicin—testicular cancer	0.000186	0.000473	CcSEcCtD
Hydromorphone—Leukopenia—Doxorubicin—testicular cancer	0.000185	0.000472	CcSEcCtD
Hydromorphone—Confusional state—Epirubicin—testicular cancer	0.000184	0.000469	CcSEcCtD
Hydromorphone—Palpitations—Doxorubicin—testicular cancer	0.000183	0.000466	CcSEcCtD
Hydromorphone—Anaphylactic shock—Epirubicin—testicular cancer	0.000183	0.000465	CcSEcCtD
Hydromorphone—Hypotension—Methotrexate—testicular cancer	0.000182	0.000465	CcSEcCtD
Hydromorphone—Loss of consciousness—Doxorubicin—testicular cancer	0.000182	0.000464	CcSEcCtD
Hydromorphone—Infection—Epirubicin—testicular cancer	0.000182	0.000462	CcSEcCtD
Hydromorphone—Cough—Doxorubicin—testicular cancer	0.000181	0.00046	CcSEcCtD
Hydromorphone—Shock—Epirubicin—testicular cancer	0.00018	0.000458	CcSEcCtD
Hydromorphone—Convulsion—Doxorubicin—testicular cancer	0.000179	0.000457	CcSEcCtD
Hydromorphone—Nervous system disorder—Epirubicin—testicular cancer	0.000179	0.000456	CcSEcCtD
Hydromorphone—Hypertension—Doxorubicin—testicular cancer	0.000179	0.000456	CcSEcCtD
Hydromorphone—Tachycardia—Epirubicin—testicular cancer	0.000178	0.000454	CcSEcCtD
Hydromorphone—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000178	0.000453	CcSEcCtD
Hydromorphone—Skin disorder—Epirubicin—testicular cancer	0.000177	0.000452	CcSEcCtD
Hydromorphone—Hyperhidrosis—Epirubicin—testicular cancer	0.000177	0.00045	CcSEcCtD
Hydromorphone—Insomnia—Methotrexate—testicular cancer	0.000177	0.00045	CcSEcCtD
Hydromorphone—Arthralgia—Doxorubicin—testicular cancer	0.000176	0.000449	CcSEcCtD
Hydromorphone—Chest pain—Doxorubicin—testicular cancer	0.000176	0.000449	CcSEcCtD
Hydromorphone—Myalgia—Doxorubicin—testicular cancer	0.000176	0.000449	CcSEcCtD
Hydromorphone—Anxiety—Doxorubicin—testicular cancer	0.000176	0.000448	CcSEcCtD
Hydromorphone—Paraesthesia—Methotrexate—testicular cancer	0.000175	0.000447	CcSEcCtD
Hydromorphone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000175	0.000446	CcSEcCtD
Hydromorphone—Discomfort—Doxorubicin—testicular cancer	0.000174	0.000444	CcSEcCtD
Hydromorphone—Anorexia—Epirubicin—testicular cancer	0.000174	0.000444	CcSEcCtD
Hydromorphone—Dyspnoea—Methotrexate—testicular cancer	0.000174	0.000443	CcSEcCtD
Hydromorphone—Somnolence—Methotrexate—testicular cancer	0.000174	0.000442	CcSEcCtD
Hydromorphone—Dry mouth—Doxorubicin—testicular cancer	0.000172	0.000439	CcSEcCtD
Hydromorphone—Dyspepsia—Methotrexate—testicular cancer	0.000172	0.000438	CcSEcCtD
Hydromorphone—Hypotension—Epirubicin—testicular cancer	0.000171	0.000435	CcSEcCtD
Hydromorphone—Confusional state—Doxorubicin—testicular cancer	0.00017	0.000434	CcSEcCtD
Hydromorphone—Decreased appetite—Methotrexate—testicular cancer	0.00017	0.000432	CcSEcCtD
Hydromorphone—Anaphylactic shock—Doxorubicin—testicular cancer	0.000169	0.000431	CcSEcCtD
Hydromorphone—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000169	0.000429	CcSEcCtD
Hydromorphone—Fatigue—Methotrexate—testicular cancer	0.000168	0.000429	CcSEcCtD
Hydromorphone—Infection—Doxorubicin—testicular cancer	0.000168	0.000428	CcSEcCtD
Hydromorphone—Pain—Methotrexate—testicular cancer	0.000167	0.000425	CcSEcCtD
Hydromorphone—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000166	0.000424	CcSEcCtD
Hydromorphone—Shock—Doxorubicin—testicular cancer	0.000166	0.000424	CcSEcCtD
Hydromorphone—Nervous system disorder—Doxorubicin—testicular cancer	0.000166	0.000422	CcSEcCtD
Hydromorphone—Insomnia—Epirubicin—testicular cancer	0.000165	0.000421	CcSEcCtD
Hydromorphone—Tachycardia—Doxorubicin—testicular cancer	0.000165	0.00042	CcSEcCtD
Hydromorphone—Skin disorder—Doxorubicin—testicular cancer	0.000164	0.000418	CcSEcCtD
Hydromorphone—Paraesthesia—Epirubicin—testicular cancer	0.000164	0.000418	CcSEcCtD
Hydromorphone—Hyperhidrosis—Doxorubicin—testicular cancer	0.000163	0.000416	CcSEcCtD
Hydromorphone—Dyspnoea—Epirubicin—testicular cancer	0.000163	0.000415	CcSEcCtD
Hydromorphone—Somnolence—Epirubicin—testicular cancer	0.000162	0.000414	CcSEcCtD
Hydromorphone—Anorexia—Doxorubicin—testicular cancer	0.000161	0.00041	CcSEcCtD
Hydromorphone—Feeling abnormal—Methotrexate—testicular cancer	0.000161	0.00041	CcSEcCtD
Hydromorphone—Dyspepsia—Epirubicin—testicular cancer	0.000161	0.00041	CcSEcCtD
Hydromorphone—Gastrointestinal pain—Methotrexate—testicular cancer	0.00016	0.000407	CcSEcCtD
Hydromorphone—Decreased appetite—Epirubicin—testicular cancer	0.000159	0.000405	CcSEcCtD
Hydromorphone—Hypotension—Doxorubicin—testicular cancer	0.000158	0.000402	CcSEcCtD
Hydromorphone—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000158	0.000402	CcSEcCtD
Hydromorphone—Fatigue—Epirubicin—testicular cancer	0.000158	0.000401	CcSEcCtD
Hydromorphone—Constipation—Epirubicin—testicular cancer	0.000156	0.000398	CcSEcCtD
Hydromorphone—Pain—Epirubicin—testicular cancer	0.000156	0.000398	CcSEcCtD
Hydromorphone—Urticaria—Methotrexate—testicular cancer	0.000155	0.000395	CcSEcCtD
Hydromorphone—Body temperature increased—Methotrexate—testicular cancer	0.000154	0.000393	CcSEcCtD
Hydromorphone—Abdominal pain—Methotrexate—testicular cancer	0.000154	0.000393	CcSEcCtD
Hydromorphone—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000154	0.000392	CcSEcCtD
Hydromorphone—Insomnia—Doxorubicin—testicular cancer	0.000153	0.000389	CcSEcCtD
Hydromorphone—Paraesthesia—Doxorubicin—testicular cancer	0.000152	0.000387	CcSEcCtD
Hydromorphone—Dyspnoea—Doxorubicin—testicular cancer	0.000151	0.000384	CcSEcCtD
Hydromorphone—Feeling abnormal—Epirubicin—testicular cancer	0.000151	0.000384	CcSEcCtD
Hydromorphone—Somnolence—Doxorubicin—testicular cancer	0.00015	0.000383	CcSEcCtD
Hydromorphone—Gastrointestinal pain—Epirubicin—testicular cancer	0.000149	0.000381	CcSEcCtD
Hydromorphone—Dyspepsia—Doxorubicin—testicular cancer	0.000149	0.000379	CcSEcCtD
Hydromorphone—Decreased appetite—Doxorubicin—testicular cancer	0.000147	0.000374	CcSEcCtD
Hydromorphone—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000146	0.000372	CcSEcCtD
Hydromorphone—Fatigue—Doxorubicin—testicular cancer	0.000146	0.000371	CcSEcCtD
Hydromorphone—Urticaria—Epirubicin—testicular cancer	0.000145	0.00037	CcSEcCtD
Hydromorphone—Constipation—Doxorubicin—testicular cancer	0.000145	0.000368	CcSEcCtD
Hydromorphone—Pain—Doxorubicin—testicular cancer	0.000145	0.000368	CcSEcCtD
Hydromorphone—Body temperature increased—Epirubicin—testicular cancer	0.000144	0.000368	CcSEcCtD
Hydromorphone—Abdominal pain—Epirubicin—testicular cancer	0.000144	0.000368	CcSEcCtD
Hydromorphone—Hypersensitivity—Methotrexate—testicular cancer	0.000144	0.000366	CcSEcCtD
Hydromorphone—Asthenia—Methotrexate—testicular cancer	0.00014	0.000357	CcSEcCtD
Hydromorphone—Feeling abnormal—Doxorubicin—testicular cancer	0.000139	0.000355	CcSEcCtD
Hydromorphone—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000138	0.000352	CcSEcCtD
Hydromorphone—Pruritus—Methotrexate—testicular cancer	0.000138	0.000352	CcSEcCtD
Hydromorphone—Hypersensitivity—Epirubicin—testicular cancer	0.000135	0.000343	CcSEcCtD
Hydromorphone—Urticaria—Doxorubicin—testicular cancer	0.000134	0.000342	CcSEcCtD
Hydromorphone—Abdominal pain—Doxorubicin—testicular cancer	0.000134	0.00034	CcSEcCtD
Hydromorphone—Body temperature increased—Doxorubicin—testicular cancer	0.000134	0.00034	CcSEcCtD
Hydromorphone—Diarrhoea—Methotrexate—testicular cancer	0.000134	0.00034	CcSEcCtD
Hydromorphone—Asthenia—Epirubicin—testicular cancer	0.000131	0.000334	CcSEcCtD
Hydromorphone—Pruritus—Epirubicin—testicular cancer	0.000129	0.000329	CcSEcCtD
Hydromorphone—Dizziness—Methotrexate—testicular cancer	0.000129	0.000329	CcSEcCtD
Hydromorphone—Diarrhoea—Epirubicin—testicular cancer	0.000125	0.000318	CcSEcCtD
Hydromorphone—Hypersensitivity—Doxorubicin—testicular cancer	0.000125	0.000317	CcSEcCtD
Hydromorphone—Vomiting—Methotrexate—testicular cancer	0.000124	0.000316	CcSEcCtD
Hydromorphone—Rash—Methotrexate—testicular cancer	0.000123	0.000314	CcSEcCtD
Hydromorphone—Dermatitis—Methotrexate—testicular cancer	0.000123	0.000313	CcSEcCtD
Hydromorphone—Headache—Methotrexate—testicular cancer	0.000122	0.000312	CcSEcCtD
Hydromorphone—Asthenia—Doxorubicin—testicular cancer	0.000121	0.000309	CcSEcCtD
Hydromorphone—Dizziness—Epirubicin—testicular cancer	0.000121	0.000308	CcSEcCtD
Hydromorphone—Pruritus—Doxorubicin—testicular cancer	0.00012	0.000305	CcSEcCtD
Hydromorphone—Vomiting—Epirubicin—testicular cancer	0.000116	0.000296	CcSEcCtD
Hydromorphone—Nausea—Methotrexate—testicular cancer	0.000116	0.000295	CcSEcCtD
Hydromorphone—Diarrhoea—Doxorubicin—testicular cancer	0.000116	0.000295	CcSEcCtD
Hydromorphone—Rash—Epirubicin—testicular cancer	0.000115	0.000293	CcSEcCtD
Hydromorphone—Dermatitis—Epirubicin—testicular cancer	0.000115	0.000293	CcSEcCtD
Hydromorphone—Headache—Epirubicin—testicular cancer	0.000114	0.000292	CcSEcCtD
Hydromorphone—Dizziness—Doxorubicin—testicular cancer	0.000112	0.000285	CcSEcCtD
Hydromorphone—Nausea—Epirubicin—testicular cancer	0.000109	0.000276	CcSEcCtD
Hydromorphone—Vomiting—Doxorubicin—testicular cancer	0.000107	0.000274	CcSEcCtD
Hydromorphone—Rash—Doxorubicin—testicular cancer	0.000107	0.000272	CcSEcCtD
Hydromorphone—Dermatitis—Doxorubicin—testicular cancer	0.000107	0.000271	CcSEcCtD
Hydromorphone—Headache—Doxorubicin—testicular cancer	0.000106	0.00027	CcSEcCtD
Hydromorphone—Nausea—Doxorubicin—testicular cancer	0.0001	0.000256	CcSEcCtD
